ACHV (40) NNNN (36) TKNO (46) QDEL (23) ⌘ Pro Terminal →

Myriad Genetics Inc. (MYGN) — RQD Stock Rating Cockpit

$6.67 +0.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.66

Myriad Genetics Inc. (MYGN) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $638.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MYGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MYGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Myriad Genetics Inc. (NASDAQ: MYGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $6.67 (+0.60% 1D, market cap $638.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MYGN ranks #376 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MYGN compare to ACHV and NNNN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), MYGN carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 69.9%, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $739.9M) and NNNN (Anbio Biotechnology (Class A)) posts a D- grade (36/100 RQD, P/E 83.6x, ROIC 17.0%, cap $535.3M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MYGN?

▼

Per MYGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899923), Myriad Genetics Inc. generated $824.5M in revenue (-1.6% YoY), -$366.0M in net income, and $1.8M in free cash flow against $706.6M in total assets and $119.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.66 (-0.08%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MYGN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY MYGN SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 75.5 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.20+0.2% Next Q

Q2 (-2Q)

Grade D$4.21+43% Next Q

Q3 (-1Q)

Grade D$6.02+10.8% Next Q

Current

Grade D$6.67-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MYGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MYGN currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.28) and Max Pain ($7.00) forces dealer call-delta covering toward $8.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MYGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MYGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERBOUGHT (>70)

75.530 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE70% OF RANGE

L: $3$6.67H: $8

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MYGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 69.9% gross margin and 0.28% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

18/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like MYGN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MYGN)

✓Walkthrough of MYGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MYGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.02%⚡ TESTING RESISTANCE

2026-11-02O $6.63H $6.67L $6.63C $6.67VOL 1.47M

RES: $6.78SUP: $1.75SMA50: $4.28SMA200: $4.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MYGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MYGN Butterfly Map → + Track MYGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MYGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MYGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MYGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MYGN)

Health Care Rank #376 of 1016 ⚔️ ACHV vs MYGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MYGN vs. ACHV, NNNN, TKNO, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Myriad Genetics Inc. (MYGN) ranks #376 by composite RQD confidence (46/100, grade D) and #415 by equity capitalization ($638.0M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MYGN ACTIVE Myriad Genetics Inc.	D	46/100	—	69.9%	-35.0%	+0.60%	$638.0M	Benchmark Subject
ACHV Achieve Life Sciences Inc.	D-	40/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-mygn →
NNNN Anbio Biotechnology (Class A)	D-	36/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-mygn →
TKNO Alpha Teknova Inc.	D	46/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-mygn →
QDEL QuidelOrtho Corporation	E	23/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-mygn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899923

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Myriad Genetics Inc. (MYGN) reported GAAP revenue of $824.5M (-1.6% vs. FY2024 revenue of $837.6M , and +9.5% cumulative change since FY2023) , GAAP net income of -$366.0M, operating cash flow of $1.8M, and free cash flow of $1.8M (+120.7% YoY). On the balance sheet, MYGN closed FY2025 with $706.6M in total assets against $119.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$824.5M	-$366.0M	$1.8M	$1.8M	$706.6M	$119.9M
FY2024 (FY)	2024-12-31	$837.6M	-$127.0M	-$8.7M	-$8.7M	$1.03B	$39.6M
FY2023 (FY)	2023-12-31	$753.2M	-$263.0M	-$110.9M	-$110.9M	—	—

3. MYGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MYGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MYGN compare to ACHV and NNNN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MYGN?

Where is MYGN trading relative to its 50-day, 200-day, and 52-week technical levels?

MYGN last traded at $6.67 (+0.60% on volume of 1,470,889 shares), positioning the stock +55.84% above its 50-day simple moving average ($4.28) and +44.69% above its 200-day simple moving average ($4.61). Across its 52-week range of $2.74 to $8.38, MYGN sits at the 69.7% percentile with a 14-day RSI of 75.5 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.84 to $7.50).

MYGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MYGN stock right now?

Myriad Genetics Inc. (MYGN) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MYGN's 12-month price target and RQD AI Jury consensus?

MYGN's 12-month base price target is $6.31 (range $4.92 to $8.8), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MYGN RQD Cockpit MYGN 12M Forecast MYGN Earnings & Move MYGN Dividends & DRIP MYGN Insiders & 13F MYGN Whale Options MYGN Profit Sankey MYGN News & Why